0000000000729712

AUTHOR

Antonio Salar

0000-0002-4652-4825

showing 2 related works from this author

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

2016

NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2-3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3-deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) a…

0301 basic medicineLymphoid TissueScienceB-cell receptorReceptors Antigen B-CellGeneral Physics and AstronomySykKaplan-Meier EstimateBiologyArticleGeneral Biochemistry Genetics and Molecular BiologyNKX2-303 medical and health sciencesChemokine receptorstomatognathic systemLYNhemic and lymphatic diseasesmedicineAnimalsHumansSyk KinaseLymphocytesPhosphorylationB cellHomeodomain ProteinsMice KnockoutCàncer -- Aspectes molecularsMultidisciplinaryCell adhesion moleculeKinaseGene Expression ProfilingQLymphoma B-Cell Marginal ZoneGeneral Chemistryrespiratory system3. Good healthMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureembryonic structurescardiovascular systemCancer researchCell Adhesion MoleculesProteïnesSignal TransductionTranscription FactorsNature Communications
researchProduct

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

2007

Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are pr…

Cancer Researchmedicine.medical_specialtyMEDLINElymphomaComorbiditySettore MED/08 - Anatomia PatologicaAntiviral AgentsImmunophenotypingDiagnosis DifferentialAntibodies Monoclonal Murine-DerivedBone MarrowAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansCombined Modality TherapySplenic marginal zone lymphomaIntensive care medicineSplenic marginal zone lymphomaNeoplasm StagingChromosome Aberrationsbusiness.industrySplenic NeoplasmsAntibodies MonoclonalDisease ManagementLymphoma B-Cell Marginal ZoneHematologyHepatitis C ChronicPrognosismedicine.diseaseCombined Modality TherapyComorbidityLymphomaSurgeryClinical trialOncologyPractice Guidelines as TopicSplenectomyRituximabDifferential diagnosisRituximabbusinessguidelineSpleenmedicine.drugLeukemia
researchProduct